1841PRefining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. (23rd October 2018) - Matos Garcia, I; García Ruiz, A; Martin-Liberal, J; Hierro, C; Ochoa De Olza Amat, M; Viaplana, C; Mur, G; Vieito Villar, M; Brana, I; Azaro, A; Perez, C; Rodriguez Freixinos, V; et al.